Lung Involvement in Primary Sjögren's Syndrome: Spectrum of Pulmonary Abnormalities and Computed Tomography Findings

NADIA RISCANEVO; RETAMOZO SOLEDAD; JUAN PABLO PIROLA; DIEGO BAENAS; MARIA JEZABEL HAYE SALINAS; ALEJANDRO ALVARELLOS; CAEIRO FRANCISCO; JANET FLORES; EMANUEL SAAD; ANA C. ALVAREZ; NADIA BENZAQUÉN

Chicago

Congreso; 2018 ACR/ARHP Annual Meeting; 2018

American Collage of Rheumatology

Background/Purpose: Primary Sjögren?s syndrome (pSS) is a chronic autoimmune disease that affects exocrine glands. It can generate pulmonary compromise due to dysfunction of the glandular epithelium of the airway.To know the prevalence of pulmonary involvement in patients with pSS in our environment; to detail clinical characteristics associated with pulmonary involvement; to compare demographic, clinical, serological and therapeutic characteristics of patients with and without pulmonary involvement in pSS.Methods: Retrospective descriptive study. Patients diagnosed with pSS (American-European criteria 2002) were included from 2010 to 2017. Abnormal salivary gland biopsy (SGB) was considered to grades III and IV of the Chisholm and Mason classification.Multivariate analyzes were performed comparing pSS with pulmonary involvement versus pSS without this involvement; p 50 mm/h was observed at the time of diagnosis in 26 (13.0%) patients, and elevated C-reactive protein (CRP) in 22 (11.0%), median value of 0.06 (RIQ 0-0.39). Anemia was observed in 14 (7.0%) patients, leukopenia in 16 (8.0%) and hypergammaglobulinemia in 47/81 (58.0%). SGB was abnormal in 179 (89.5%), grade III in 75 (37.5%) and IV in 104 (52.0%). Regarding treatment, 61 (30.5%) received hydroxychloroquine, 56 (28.0%) prednisone